Skip to main content

Featured Studies

This web page makes it easy to search for featured research studies at the NIH Clinical Center. You can search for specific studies by entering keywords related to your symptoms in the search box or by using the sort and filter options.


To view a full list of all studies conducted at the NIH Clinical Center, visit Search the Studies.

Filter By

Visit Type

Patient or Healthy Volunteer

Age Group

Institution

Web Page Language

62 results
Famine from Feast: Linking Vitamin C, Red Blood Cell Fragility, and Diabetes

Famine from Feast: Linking Vitamin C, Red Blood Cell Fragility, and Diabetes

The National Institutes of Health (NIH) researchers are enrolling adult volunteers in a study investigating the role of Vitamin C in red blood cells of patients with type 2 diabetes. Findings may help improve future treatment and care of people with diabetes.
Learn More
NIH Research of Multiple Sclerosis and Related Conditions

NIH Research of Multiple Sclerosis and Related Conditions

The National Institutes of Health (NIH) is conducting a research study of the causes and responses to treating multiple sclerosis (MS) and other brain and spine inflammatory conditions. Join this study if you have MS or a related disease. Although the study does not offer treatment options, your participation may help in future discoveries and inspire hope.
Learn More
Clinical Evaluation of Pediatric and Adults with Myelodysplastic Syndromes (MDS)

Clinical Evaluation of Pediatric and Adults with Myelodysplastic Syndromes (MDS)

Myelodysplastic syndromes (MDS) are disorders caused by abnormal blood cell production, potentially leading to low cell counts and increased susceptibility to clotting and infections. Past research suggests that inflammation may trigger these abnormalities, and this study seeks to further understand and improve treatment strategies for MDS by investigating the role of inflammation in bone marrow cell development.

Learn More
The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients with Systemic Lupus Erythematosus

The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients with Systemic Lupus Erythematosus

People with systemic lupus erythematosus (SLE) are at risk of developing complications in their blood vessels. The risks increase for heart attacks or stroke. No medications have been effective at reducing this risk in people with lupus. Researchers at NIH are testing whether a drug (anifrolumab) can improve blood vessel function and reduce blood vessel inflammation in people with (SLE). Participants do not pay for tests, treatments, or procedures.
Learn More
Observational Study of Cardiac Arrhythmias in Subjects Treated with BTK Inhibitors

Observational Study of Cardiac Arrhythmias in Subjects Treated with BTK Inhibitors

Pharmacologic therapy with Bruton's tyrosine kinase (BTK) inhibitors is associated with an increased risk of heart problems like atrial fibrillation, bleeding, and high blood pressure (hypertension) which can lead to sudden death. There is currently no standard for cardiac screening or monitoring patients on BTK inhibitors. Researchers at the National Heart, Lung, and Blood Institute (NHLBI) are investigating the relationship between the development of heart problems in patients on BTKi as it relates to other variables.
Learn More
NIH Tests Fostamatinib for Post-Transplant Cytopenia(s)

NIH Tests Fostamatinib for Post-Transplant Cytopenia(s)

After stem cell transplantation, some people develop hard-to-treat anemia (low red blood cells) or thrombocytopenia (low platelets). Cytopenia(s) or low blood cell counts make you weak, prone to bleeding and bruising, and dependent on blood product transfusions. Researchers at the National Institutes of Health (NIH) are testing the drug fostamatinib to see if it is safe to treat cytopenia(s) after stem cell transplantation. A physician referral is not required to participate.

Learn More
Research Study for Severe Aplastic Anemia (SAA)

Research Study for Severe Aplastic Anemia (SAA)

Doctors at the National Institutes of Health (NIH) are conducting a research study to determine the viability and safety of early initiation of oral therapy with cyclosporine and eltrombopag in patients with severe aplastic anemia (SAA).

Learn More
Dietary Behavior Intervention

Dietary Behavior Intervention

The risk of heart disease among African Americans is still common despite a greater understanding of the disease and better approaches to managing it. Healthy cooking and eating patterns can help reduce the risk of heart disease. But things like access to grocery stores and knowledge of good nutrition can affect these healthy patterns. Researchers at The National Institutes of Health want to see if community-based programs can help.
Learn More
Phase I/II Trial of Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination with HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants with Advanced or Metastatic Endometrial Cancer (EC)

Phase I/II Trial of Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination with HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants with Advanced or Metastatic Endometrial Cancer (EC)

Researchers from the National Cancer Institute at the NIH Clinical Center are currently looking for patients who have HER2-expressing endometrial cancer. The purpose of the study is to test two investigational study drugs, a vaccine that targets HER2 (AdHER2DC) and a drug that is expected to improve immune cell function (N-803). These study drugs will be used with pembrolizumab and lenvatinib which are FDA approved to treat endometrial cancer.
Learn More
Studies of the Natural History of Sickle Cell Disease

Studies of the Natural History of Sickle Cell Disease

The research study aims to enhance the understanding of SCD and its associated complications by investigating the relationship between the disease and specific variations of certain genes. If you have SCD, your participation in this study is highly valuable. By participating, you will undergo an evaluation and receive recommendations from a team experienced in the treatment and management of SCD.

Learn More
Was this page helpful?